Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
June 27 2024 - 8:00AM
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or
“Quoin”), a clinical stage specialty pharmaceutical company focused
on rare and orphan diseases, today announces that it will expand
its ongoing Netherton Syndrome clinical studies to include
international sites. The first international site will be opened at
a research hospital in Saudi Arabia. This hospital is currently
treating a number of Netherton patients who will now become
eligible for recruitment into Quoin’s studies. An experienced
Clinical Research Organization has been engaged to manage the study
locally. The Saudi site will operate under the auspices of Quoin’s
open Investigational New Drug (IND) application with the US Food
and Drug Administration. Plans to open additional international
clinical sites are at an advanced stage.
Quoin CEO, Dr. Michael Myers, said, “We are very
pleased to announce this exciting development for our ongoing
clinical studies. We hope that the opening of this first
international site, which is currently treating Netherton patients,
will speed up overall recruitment into our studies whilst expanding
the diversity of the patient population being tested. We are
working hard to open additional international sites to augment the
five sites that are currently open in the US. Quoin is committed to
completing recruitment into our clinical studies as expeditiously
as possible with a view to potentially delivering the first
approved treatment to this underserved patient population.”
Quoin is conducting two ongoing clinical trials
evaluating QRX003, a topical lotion, for the treatment of Netherton
Syndrome. For more information about the trials, please visit:
https://www.nethertonsyndromeclinicaltrials.com/.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage
specialty pharmaceutical company focused on developing and
commercializing therapeutic products that treat rare and orphan
diseases. We are committed to addressing unmet medical needs for
patients, their families, communities and care teams. Quoin’s
innovative pipeline comprises five products in development that
collectively have the potential to target a broad number of rare
and orphan indications, including Netherton Syndrome, Peeling Skin
Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis
Bullosa and others. For more information, visit:
www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding
Forward Looking Statements
The Company cautions
that statements in this press release that are not a description of
historical facts are forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements may be identified by the use of words
referencing future events or circumstances such as “expect,”
“intend,” “plan,” “anticipate,” “believe,” and “will,” among
others. All statements that reflect the Company’s expectations,
assumptions, projections, beliefs, or opinions about the future,
other than statements of historical fact, are forward-looking
statements, including, without limitation, statements relating to
the conference’s aim of connecting individuals seeking information
about ichthyosis and other skin disorders, the Company delivering a
safe and effective treatment for Netherton Syndrome as
expeditiously as possible, and the Company’s four products in
development collectively having the potential to target a broad
number of rare and orphan indications, including Netherton
Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma,
Scleroderma, Epidermolysis. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon the Company’s
current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Actual results and the
timing of events could differ materially from those anticipated in
such forward-looking statements as a result of various risks and
uncertainties including, but not limited to, the Company ability to
deliver a safe and effective treatment for Netherton Syndrome, the
preclinical and clinical studies of the Company’s product
candidates may not be successful and other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2023 that the Company filed with the SEC and the Company’s
subsequent filings with the SEC on Forms 10-Q and 8-K. One should
not place undue reliance on these forward-looking statements, which
speak only as of the date on which they were made. The Company
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made, except as may be required by law.
For further information, contact:Investor
RelationsPCG AdvisoryJeff Ramsonjramson@pcgadvisory.com(646)
863-6341
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Quoin Pharmaceuticals (NASDAQ:QNRX)
Historical Stock Chart
From Nov 2023 to Nov 2024